An update from Inventiva ( (IVA) ) is now available.
On February 20, 2025, Inventiva, in collaboration with Hepalys Pharma, announced the initiation of a clinical development program for lanifibranor in Japan, marking the first dosing of a participant in a Phase 1 trial. This trial is a significant step in their partnership to introduce lanifibranor in Japan and potentially South Korea, targeting a market with a substantial MASH patient population. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of lanifibranor, with positive results potentially leading to a pivotal Phase 3 trial. This development underscores Inventiva’s strategic move to leverage Hepalys’s local expertise for successful market entry in Asia, where the demand for MASH treatments is growing.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs. The company is conducting clinical trials for its lead product candidate, lanifibranor, a pan-PPAR agonist designed to treat MASH. Inventiva is publicly traded on Euronext Paris and Nasdaq, boasting a robust scientific team and an extensive library of pharmacologically relevant molecules.
YTD Price Performance: 26.64%
Average Trading Volume: 9,066
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $233.9M
For detailed information about IVA stock, go to TipRanks’ Stock Analysis page.